BioCentury
ARTICLE | Clinical News

Vidaza azacitidine regulatory update

January 5, 2009 8:00 AM UTC

The EC approved Vidaza azacitidine from Celgene to treat myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myelogenous leukemia (AML) in adults who are not eligible for...